Enrolling

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)

The purpose of this study is to determine the long-term safety of the study intervention orforglipron as monotherapy or in combination with oral antihyperglycemic medication.

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Orforglipron
Could I receive a Placebo?
No
Enrollment Goal
399
Trial Dates
Sep 28, 2023 - Jun 2025
How long will I be in the trial?
The study will last about 58 weeks and may include up to 13 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have Type 2 diabetes

  • Have overweight

Participants Must Not:

  • Have Type 1 diabetes

  • Have severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening, or between screening and randomization.

  • Have heart attack, stroke or congestive heart failure within 60 days prior to screening

  • Have pancreatitis

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources